Romans give us the current English word "dementia," which they used with similar meaning.
Alzheimer's first patient with dementia had the early onset form of AD. In an oral communication in 1906, published in 1907, he reported the case of Auguste Deter, a 51-year-old woman with delusions, severe memory loss, disorientation, language deficits, and behavioral disturbances. She had been institutionalized in Frankfurt for these symptoms but continued to decline until she was bedridden and died 4.5 years later.
1 Autopsy revealed a diffuse atrophic brain without macroscopic focal degeneration. Microscopic examination showed "tangles of fibrils," neuronal loss, and "deposition of a special substance in the cortex [that] can be observed without dye, but it is very refractory to dyeing." We have here the complete picture of AD as is currently defined: a progressive cognitive decline focusing on memory leading to dementia, associated with neurofibrillary tangles (revealed later to be the result of hyperphosphorylated tau protein deposits) and the special substance that was found later to be an accumulation of amyloid A-β proteins (see chapter on Neuropathology and the work by Hyman et al).
5
Alzheimer thought this condition was "eine eigenartige Erkrankung der Hirnrinde" (title of the 1907 Alzheimer's article), i.e., an unusual illness of the cerebral cortex. The following years saw many more descriptions of the same brain lesions identified both in early-and late-onset cases (i.e., senile dementia). Remarkably, Oskar Fischer's clinicopathological study of 16 patients diagnosed with senile dementia came out in the very same year as Alzheimer's. It is in this study that we find the first description of neuritic plaques. 6 In spite of this, 3 years later Kraepelin decided to name after Alzheimer presenile dementia cases he identified as distinct from senile dementia. As discussed elsewhere, it is not entirely clear what led Kraepelin to do so. [7] [8] [9] The distinguishing characteristics he cites for early-onset AD (EOAD) are patients' relative youth, severe dementia, focal signs, and language disturbances. These characteristics we acknowledge today distinguish EOAD and late-onset AD (LOAD). Alzheimer himself objected to the link Fischer claimed existed between presbyophrenic dementia (agingrelated dementia) and plaques. 10 While he concurred with the fact that plaques occurred more frequently in cases of presbyophrenic dementia, he did not believe them to be pathognomonic for this condition. Plaques in his view were a marker of senile dementia, but without causing the condition. In line with this point of view, Kraepelin's textbook established a distinction which remained predominant within the scientific and medical circles for much of the 20th century, and commentators continued to rely on the old diagnostic categories of senility or senile dementia to describe a rather wide variety of commonly recognized symptoms and behaviors. They traced the etiology of these clinical symptoms to an equally wide variety of causes, all more or less loosely related to the phenomenon of old age. The "Fischer/Alzheimer-Kraepelin debate" finally reemerged and was eventually settled in favor of Fischer's point of view during the last quarter of the 20th century. Furthered by demographic, political, and scientific developments (see Boller's 4 study for a review), senile dementia became increasingly common within the aging population, beyond what could be explained by the arteriolosclerotic lesions or other known phenomena of old age. In reaction to the situation, particular attention was given to the pathological hallmarks of senile dementia and Fischer's work in the area was met with renewed interest. For example, the white paper authored by Robert Katzman, Robert Terry, and Katherine Bick at the conclusion of a 1977 workshop conference, co-organized by National Institute on Aging (NIA), National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), and National Institute of Mental Health (NIMH) and held in Bethesda, concluded: "there is increasing recognition that most patients with clinically defined senile dementia (onset after age 65) manifest the same pathological changes in their brains as do patients in their presenium (under age 65) with Alzheimer's disease."
11
A growing consensus following the same lines helped bring Alzheimer research into the modern era by "officially" acknowledging AD as a condition affecting patients in old age.
AD as a Clinicopathological Entity and Cause of Dementia
Seven years later, the publication of the NINCDS-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria of AD confirmed AD as a disease, independent of age of presentation, and therefore as a cause of senile dementia.
12 Three cornerstones of these criteria were that: (1) any antemortem clinical diagnosis of AD could be made merely on a "probable" basis, while (2) final and definite diagnosis was possible upon postmortem examination only, and (3) the diagnosis could only be applied when the disease was advanced to the functional disability threshold of dementia. The NINCDS-ADRDA criteria established a two-step procedure for the diagnosis of probable AD. First, establishing the existence of a dementia syndrome by means of medical examination and neuropsychological testing, revealing deficits in at least two areas of cognition, one of which had to be memory. These deficits were required to be sufficiently pronounced as to significantly impact patients' daily functioning. Upon this initial identification of a dementia syndrome, the second step consisted of the exclusion of other However, only 70% of amnestic MCI cases (the most specific cases regarding AD phenotype) who have progressed to dementia actually met neuropathological criteria for AD.
17
In parallel, NINCDS-ADRDA criteria for probable AD were found to suffer from much the same lack of specificity, with sensitivity of the criteria in a tertiary center estimated to be 70.9 to 87.3%, and its specificity 44.3 to 70.8%.
18
From a Clinicopathological Definition to a Clinicoradiobiological Definition NINCDS-ADRDA and MCI criteria enabled researchers to follow clinical cases and to better characterize the disease. First, the clinical phenotype of AD was elucidated: in more than 85% of cases, AD presents as a progressive amnestic disorder with a specific episodic memory impairment profile characterized by low free recall that is not improved by cueing. This distinguishes AD from normal aging and non-AD disorders. It is also useful for predicting conversion to AD in MCI patients 19 (see below). Second, postmortem studies of AD patients showed a specific hierarchical pattern of tau pathology, which begins in the memory-related areas of medial temporal lobe structures (entorhinal cortex, hippocampal formations, parahippocampal gyrus). 20, 21 In contrast, β amyloid deposits are more diffuse in the neocortex before spreading to the deep nuclei, the pons, and the cerebellum. 20, 22 The AD-specific episodic memory profile proved to correlate significantly with hippocampal volume and, more precisely, with the CA1 field. 23, 24 Third, diagnostic accuracy of AD was also improved because of a better characterization of non-AD neurodegenerative diseases through specific criteria. These other dementias included primary progressive aphasias, corticobasal syndrome, frontotemporal dementias, and Lewy body dementia. The identification of these diseases, which were previously highly confused with AD, has consequently decreased its apparent heterogeneity. Finally, reliable biomarkers for AD were isolated and have now become available at least in expert centers. The incremental gains in diagnostic accuracy due to biomarkers is now well established.
Hence, a new conceptual framework for the diagnosis of AD has been proposed by the International Working Group (IWG) 28 and later by the NIA/Alzheimer's Association (NIA/ AA) 29 based on two requirements: (1) earlier diagnosis and (2) greater specificity. In 2007, the IWG provided a new conceptual framework, according to which AD moves from a clinicopathological entity to a clinicoradiobiological entity.
28
The 2007 IWG criteria stipulated that AD can be recognized in vivo in the presence of two associated features. The first is the evidence of an "amnestic syndrome of the hippocampal type" seen in the typical form of the disease. The importance of a specific memory pattern was highlighted because it occurs early in the course of the disease and it is fairly specific, though not pathognomonic, for AD. The second necessary feature was supportive evidence from biomarkers that were proposed for the first time for the diagnosis of AD. The biomarkers of AD were divided into two groups: (1) the pathophysiologic markers-positive positron emission tomography (PET)-amyloid scan or CSF AD profile (low Abeta 42 level, high total tau, and high phospho-tau); these markers identified AD pathology since they were strongly correlated with postmortem AD histopathological changes; (2) topographical markers: hippocampal atrophy on volumetric MRI or cortical regional hypometabolism on fluorodeoxyglucose-PET (FDG-PET) especially the posterior associative areas including the posterior cingulate cortex (see chapter on Neuroimaging). These reflected downstream damage and were rather markers of progression, more targeted at assessing change over time and predicting outcomes. As a consequence, CSF and MRI investigations were no longer simply for excluding other etiologies of brain dysfunction but were central to detecting AD-related changes. An important clarification of the above criteria was brought forward in 2010, introducing the concept of "atypical forms of AD" and proposing corresponding criteria and a diagnostic framework. 30 An amnestic presentation for AD may not always be the case, and other specific clinical phenotypes could be associated with postmortem evidence of AD pathology. These specific clinical phenotypes included nonamnestic focal cortical syndromes, such as logopenic aphasia, biparietal atrophy, posterior cortical atrophy (PCA), and frontal variant AD (see below). These clinical disorders were more commonly seen and treated as atypical AD, as biomarkers began to allow in vivo confirmation of Alzheimer's pathology. Individuals without clinical symptoms but with positive biomarkers of Alzheimer pathology were considered "asymptomatic at risk of AD." "Asymptomatic at risk for AD" was used for subjects without cognitive dysfunction but evidence of amyloidosis in the brain (on PET amyloid) or AD-related changes in the CSF. The stage "presymptomatic AD" was ascribed to individuals carrying autosomal dominant monogenic AD mutations (see below) who would with time inevitably develop clinical AD, provided they lived long enough. Finally, topographical markers were no longer used because of their lack of specificity regarding AD. Thus, the only validated biomarkers for AD diagnosis were defined as CSF low Aβ42 and high T-tau or P-tau levels or evidence of amyloid retention in amyloid PET.
In line with the conceptual evolution, the NIA/AA published diagnostic criteria in 2011, 29 which refined the NINCDS-ADRDA framework to broaden the coverage of different stages of disease from the asymptomatic (preclinical), through the predementia stages (MCI due to AD), to the most severe stages of dementia. These shared many features with the IWG criteria, including the recognition of an asymptomatic but biomarker-positive phase and of a predementia symptomatic phase of AD. Biomarkers were given an important place in the diagnostic process, first in identifying amyloid abnormalities and second in identifying downstream neurodegeneration. These biomarkers also had the advantage of being usable in both clinical and research settings. and (4) none of the biomarkers was static-rates of change in each biomarker changed over time and followed a nonlinear time course. There are several important differences between the NIA/ AA criteria and those from IWG. The NIA/AA framework held that the presence of Alzheimer pathology indicates the diagnosis of AD, and that this diagnosis is applicable at this "in situ" stage for research purposes. At the predementia MCI stage, the framework applied a probabilistic likelihood based on the presence of AD biomarkers with designation either of biomarkers that reflect amyloidosis (CSF Abeta or amyloid PET) or those that are "downstream" indicative of neuronal degeneration (CSF phospho or total tau, FDG glucose, and volumetric MRI). Based on positive, negative, or intermediate results on the "amyloid" and "downstream" biomarkers-or the absence thereof-a probabilistic likelihood of "high" or "intermediate" was applied to the diagnosis. In contrast to IWG criteria, the MCI stage of AD was formally distinguished from the dementia stage, which had its own diagnostic criteria. In the dementia stage, 10 categories of dementia of the AD type were established, including probable AD dementia, possible AD dementia, probable or possible AD dementia with evidence of the AD pathophysiological process, and pathophysiologically proved AD dementia. The probable or possible AD dementia stages retained most of the features of the 1984 NINCDS-ADRDA diagnosis of probable AD 12 despite the low specificity, limited positive predictive value, and poor negative predictive value of these criteria.
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On the basis of the 2010 preliminary paper, the IWG formalized its criteria in 2014. 37 In addition, they refined the definition of the typical amnestic AD, identified with the use of list-learning and other episodic memory tests . They also introduced the notion of a copathology in AD with the diagnosis of mixed AD when a patient had in addition to AD a coexisting disorder identified by evidence of specific clinical and biological features of another disease, such as parkinsonism (for Lewy body disease) or cerebrovascular disease. Additional formalizations concerned the preclinical state of AD, including the "asymptomatic at risk of AD" and "presymptomatic AD" previously described.
We can conclude that the main contribution of the IWG and NIA/AA criteria lies in the refinement they brought to the diagnosis of AD prior to the onset of dementia and their inclusion of biomarkers of Alzheimer's pathology into the diagnostic framework. Beyond this, their methodology proved useful with clinical trials and possibly with regulatory decisions. They could also set the stage for primary and secondary prevention.
From a Clinicoradiobiological Definition to a Pure Biological Definition
In 2016, the joint IWG/AA meeting furthered the integration of biomarkers into the definition of AD and decided to apply this definition independent of the clinical status. 38 Indeed, the new definition of AD is now purely biological and is based on the positivity of biomarkers of both amyloidosis and tauopathy independent of the clinical status. The cognitive changes are now considered as a stage of the disease which refers to a degree of disease progression (preclinical ¼ asymptomatic, prodromal ¼ cognitive deficit with no impact in the daily living activity, and dementia ¼ cognitive deficit with impact in the daily living activity). Thus, asymptomatic individuals with positive biomarkers (evidence of both amyloid and tau biomarkers) are no longer considered "asymptomatic at risk of AD" but as the earliest form of AD (preclinical AD). As a result, the IWG/AA criteria considered that the category "asymptomatic at risk for AD" still applies in the case of discrepant amyloidosis and tau biomarker results (evident in cognitively normal individuals of isolated Aß pathology or of isolated Tau pathology). The NIA/AA have recently formalized this new biological definition of AD. 39 They propose an A/T(N)(C) classification relying on CSF, PET, and MRI biomarkers (A ¼ amyloid; T ¼ tauopathy; N ¼ neurodegeneration; C ¼ cognitive change), where A and T positivity define AD while N and C are not specific to AD and define the severity stage of the disease. Hence, in line with the IWG/AA 2016 paper, the focus of these criteria is no more on the symptoms but on the biological in vivo definition of the disease. Besides, in line with the conceptual evolution that tauopathy might not only be the downstream consequence of amyloid pathology but a parallel and independent pathological process, 40-45 the hierarchy between amyloid and tau biomarkers has been softened and concomitant tauopathy and amyloidosis now represent AD. Amyloid biomarkers validated by these criteria are CSF Aβ42, or Aβ42/Aβ40 ratio and amyloid-PET. Aggregated tau (neurofibrillary tangles) validated biomarkers include CSF phosphorylated tau and tau-PET. Finally, biomarkers representing neurodegeneration are structural MRI, FDG-PET, and CSF total tau. Nonetheless, no technical measures or thresholds are settled in these criteria, and it is clearly stated that these biomarkers will be evolving as research progresses. Clinical definitions are restricted to the clinical phase of AD: cognitively unimpaired (normal performing subjects on cognitive testing, may report subjective cognitive decline), MCI (evidence of cognitive impairment and evidence of decline in cognitive performance from baseline in an individual who performs daily living activities independently), and dementia (substantial progressive cognitive impairment that affects several domains and/or neurobehavioral symptoms and results in a clearly evident functional impact on daily life).
As a whole, individuals who fulfill both the A and T biomarker criteria qualify as having AD (preclinical AD or AD with MCI or AD with dementia). Individuals who fulfill the A biomarker criteria without the T biomarker are classified as Alzheimer's pathologic change (preclinical, with MCI or with dementia), 31, 41 while individuals who fulfill the T biomarker criteria without the A biomarker are classified as non-Alzheimer's pathologic change (such as the A negative, T negative, and N positive individuals), in keeping with the NIA/AA pathologic definition of primary age-related tauopathy (PART) as not AD. 45 There is currently no data regarding the risk of developing subsequent AD amongst individuals diagnosed with PART. In line with the mixed AD concept introduced by the IWG criteria, the NIA/AA criteria also allow for this concept under the term "suspected Alzheimer's" and concomitant suspected non-Alzheimer's pathologic change when there is an incomplete biomarker combination (e.g., A þ T-Nþ). In this context, the presence of other dementias may be uncertain, since biomarkers for other neurodegenerative diseases lack of specificity/ sensitivity. When no biomarker is available, the 2018 NIA/AA criteria introduced the concept of Alzheimer's clinical syndrome, which applies to both mildly impaired and demented individuals. This refers to the definitions of possible and probable AD according to the previous NINCDS-ADRDA 12 and NIA/ AA 46 criteria. Nonetheless little is said regarding the precise phenotype except a vague "multi-(or single-) domain amnestic syndrome" or a "classic syndromal variant."
Research versus Clinical Criteria
More recent clinical criteria allow earlier and more accurate diagnosis of AD, but are very much dependent on the availability of suitable biomarkers. This is problematic, since as much as 58% of those suffering from dementia live in lowand middle-income countries, according to a report of AD International. 47 Sophisticated, high-tech screenings for biomarkers are not universally available, even in high-income countries, and often limited to tertiary or research centers. This mostly limits the applicability of diagnostic approaches proposed in recent years to these contexts, i.e., facilities able to screen for a large variety of biomarkers and with access to normative data. These conditions allow for complex diagnoses such as EOAD, frontal variant AD, or primary progressive aphasias, where biomarkers are essential for sufficient accuracy in diagnosis. In less favorable circumstances, the clinical syndrome definition of AD as put forward by NIA/AA may be used for diagnosis. Finally, the predictive value of these biomarkers in asymptomatic populations needs to be confirmed to validate criteria for the preclinical stages. Indeed, while they have largely proved their ability to predict cognitive decline in patients with MCI, 26 for a review). The incidence of AD increases exponentially with age, plateauing around 85 years of age. After 85 years of age, different studies find diverging resultseither a decline in incidence, stable incidence rates, or a deceleration in the increase in incidence rate. [63] [64] [65] [66] [67] Interestingly, as the incidence of AD rates decreases with advanced old age, the incidence of "pure" vascular dementia also decreases, while mixed pathologies show greater incidence with extremely old age. 68 As a whole, this allows us to have only a rough estimation of AD prevalence. The World Alzheimer Report 2015 69 estimated that 46.8 million people have dementia around the world, with an estimated yearly cost of 880 billion U.S. dollars. Using these numbers, one can estimate the number of people with AD to be 30 million (including pure and mixed AD cases) around the world. The mean duration of survival with AD is estimated to be 5 to 6 years at the time of the dementia stage of the disease, and longer with earlier age at onset. It therefore reduces life expectancy.
70,71
The frontier between EOAD and LOAD has been somewhat arbitrarily defined by age at first manifestation of symptoms (< or >65 years). LOAD represents the vast majority of AD cases (>95%). 72, 73 Nonetheless, EOAD remains the most common cause of early-onset neurodegenerative dementia. In contrast to LOAD, which is a complex disorder with a heterogeneous etiology and a heritability (according to some models) of 70 to 80%, EOAD is almost entirely genetically determined, with a heritability ranging between 92 and 100%. 74, 75 Between 35 and 60% of EOAD patients have at least one affected first-degree relative, and in 10 to 15% of associated with risk of AD onset, the associations are weak, at best, for a majority of factors. Nonetheless, as stated earlier, the vast majority of these studies have been conducted without biomarkers. For instance, in clinical-autopsy studies, diabetes was associated with cognitive impairment (and the clinical diagnosis of probable AD); however, the pathologic basis for this association was vascular brain injury and not Aβ plaques and neurofibrillary tangles. [85] [86] [87] Thus, there is a need to disentangle AD from dementia, using the new biological definition of the disease, to update well-known established data regarding epidemiology and genetic risk factors of the disease.
Alzheimer's Disease Clinical Phenotypes
The recent focus on the biological definition of the disease should not give us a cause to neglect clinical phenotypes of AD in the prodromal or dementia stages of the disease. Given the lack of an efficient disease-modifying treatment, the need in clinical practice for a biological preclinical diagnosis remains low. The appearance of such treatments in the future may change this. Meanwhile, we still need to identify in clinical practice the specific phenotypes and indications for a reasonable and relevant use of MRI, CSF, PET, and blood tests.
IWG typical and atypical AD phenotypes
Regarding this specific question, the IWG 2014 criteria are the most recent criteria specifying the specific clinical phenotypes of the disease. Typical AD is the progressive amnestic presentation of the disease, described long before the discovery of AD itself (►Fig. 3). 88 The memory disorder of AD is complex and varies with the stage of the disease. 88, 89 In 1881, Ribot first described progression of memory deficits amongst patients who went on to develop senile dementia: "The progressive destruction of memory follows a logical progression, a law. It goes from unstable to stable. It starts with recent memories, weakly settled in the nervous elements, seldom repeated and consequently weakly associated to the others, which represent the weakest level of organization. It ends up with this instinctive, sensorial memory, settled in the organism that has become a part of it, or even the organism itself, which represents the strongest level of organization." 88 We now know that the earlier symptoms described by Ribot corresponded to episodic memory impairment. The famous case studies of HM and KC, with lesions of the hippocampus, later localized episodic memory to the hippocampus. 90, 91 To quantify episodic memory deficits, Grober et al 92 developed, at the end of the 1980s, a free and cued selective reminding test (FCSRT), a list-learning test that controls for successful encoding (achieved by cued recall) and facilitates retrieval processing (with the same semantic cues) of new words in episodic memory. With this they highlighted an amnestic pattern specific to AD as opposed to normal aging and other dementias. The test in AD patients often showed a low immediate recall score and a low performance despite cueing across successive Alzheimer's Disease Including Focal Presentations Villain, Dubois 219
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rehearsals/recall trials. 19, 92, 93 Moreover, AD patients also produce numerous intrusions, i.e., the patient offers a word which was not in the list of words to be remembered.
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This pattern has been confirmed years later using biomarkerbased criteria. 95 Impaired FCSRT performance can be correlated with hippocampal atrophy, gray matter loss of the medial temporal lobe, and the presence of Alzheimer's CSF biomarkers, even during the prodromal stage. 23, 24, [96] [97] [98] [99] It has shown discriminative utility for predicting conversion to AD in MCI patients. 100 Hence, the FCSRT is specifically recommended in the IWG criteria. Other tests which can be useful in identifying the amnestic syndrome of AD focus on list learning and delayed recall of information, for example paired-associate learning and the Rey auditory verbal learning tasks. 101 The DMS48 tests visual recognition and has shown to correlate with AD patterns in patients with MCI. 102 It is one of the several neuropsychological tests designed to identify amnestic impairment with a pattern which is specific for early pathological involvement of the entorhinal-perirhinal cortex. The short-term memory binding test might also be a good marker for AD given its high specificity in patients with familial AD and in asymptomatic carriers with PSEN1 autosomal dominant gene mutations.
103,104
The natural history of AD is progression of cognitive decline and spread to other cognitive domains, for example, other memory systems than episodic memory, aphasia, apraxia, visuospatial functions, executive functions, etc.
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In addition, various neuropsychiatric disturbances can be observed in patients with AD: apathy, dysphoria, and agitation are common during the course of the disease. 105 In the early stages of AD, apathy, expressed by profound disinterest in nonroutine and interpersonal activities, can often be observed, whereas psychosis (delusions or hallucinations) is more typical for advanced AD. Deterioration of cognition and behavior to a level which interfere with activities of daily living is the basis of a diagnosis of dementia. Ultimately, loss of self-care, eating, dressing, ambulation, incontinence, and motor dysfunction lead to bedridden status and death.
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Epilepsy (generalized convulsive seizures or complex partial seizures) can also occur in AD, but is not among the commonest manifestations of the disease. 107 Younger age and increasing dementia severity are the most reliable risk factors for seizures in AD.
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Main differential diagnoses for this clinical form encompass all neurodegenerative diseases that target the hippocampus early and preferentially. The long list of differential diagnoses includes cerebral age-related hippocampal sclerosis with TDP-43 (CARTS), 62, 108 
135-138
The language variant of AD, which presents as logopenic variant primary progressive aphasia, is defined by a progressive impairment in single-word retrieval and in repetition of sentences in the context of spared semantic, syntactic, and motor speech abilities (►Fig. 3).
139 AD represents, according to neuropathological series, approximately 55 to 100% of logopenic primary progressive aphasias, while other etiologies include FTLD-tau or TDP, CBD, and prion-associated diseases (►Fig. 3).
140-142
The frontal variant of AD presents similarly to the behavioral variant of frontotemporal dementia, with progressive apathy or behavioral disinhibition, stereotyped behaviors, and predominant executive dysfunction on testing.
143-145
The behavioral predominant variant of AD is usually an EOAD with more severe dysexecutive than behavioral features, while episodic memory is usually impaired (►Fig. 3).
145
On the other hand, the dysexecutive-predominant variant AD is also usually an EOAD with a relatively pure dysexecutive syndrome, while behavior and episodic memory are usually relatively spared (►Fig. Alzheimer's Disease Including Focal Presentations Villain, Dubois 221
and includes a higher percentage of nonamnestic cognitive syndromes: 22 to 64% of patients with EOAD can have predominant cognitive syndromes involving language, visuospatial abilities, behavioral/executive functions, and limb praxis. These cognitive syndromes can also differ from typical AD in that they have a higher mortality,
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potentially different predisposing factors (see above), and neuropathological involvement (relative hippocampal sparing, relatively greater tau burden and greater white matter involvement, and selective vulnerability of long, projection neurons). The three pathogenic gene mutations, PSEN1, APP, and PSEN2, which lead to aberrant cleavage or aggregation of the APP, result in the more typical amnestic AD, but can also have distinctive features such as spastic paraparesis, early myoclonus, seizures, dysarthria, pseudobulbar affect, more extensive amyloid angiopathy, and atypical amyloid plaque morphology and distribution.
158
Auguste Deter had severe language impairment and limb apraxia, which may have been worse than her memory impairment. Hence, Alois Alzheimer's original patient was a nonamnestic presentation with EOAD, though there is still a debate on whether she had a PSEN1 mutation or not.
159,160
As we have seen, current data confirm that LOAD and EOAD have differences in terms of epidemiology, neuropathology, and clinical presentation. Thus, current data to some extent support both sides of the "Fischer/Alzheimer-Kraepelin debate" we outlined earlier 161 even if nowadays there is more evidence to consider them as two variants of a same disease than different diseases.
Conclusion
The definition of AD has changed fundamentally in the past 30 years (►Fig. 1). AD and its variants continue to challenge the physician, with the ever-diversifying neurodegenerative disease which can mimic AD. We now know that neuropathologies co-occur, especially with increasing age, but we do not yet know the provenance of this newfound complexity (►Fig. 2). Research on neuroimaging or biological biomarkers should help us disentangle these diseases and help us design better clinical trials. With the shift from a clinical definition to biological definitions for AD, we may look more suspiciously at older epidemiological data, and by renewing the data in light of biomarkers be better in discovering risk factors, mechanisms, and therapies.
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